FDA rejection

Aldeyra Therapeutics plummets 71% after FDA rejects lead dry eye drug. Securities litigation firm investigating potential investor claims following efficacy concerns.

Hagens Berman files securities class action against $CORT after FDA rejection of lead drug and federal court patent loss, alleging concealment of clinical data warnings.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.

FDA rejects Disc Medicine's bitopertin drug, triggering 22% stock decline and securities investigation into potential investor losses.

FDA rejects Corcept's lead drug candidate, triggering 50% stock plunge and securities class action lawsuit. Lead plaintiff deadline set for April 21, 2026.

Aldeyra Therapeutics ($ALDX) shares crashed 65% following FDA rejection of reproxalap for dry eye disease. Law firm Block & Leviton investigates potential securities fraud.

$CORT stock plummets 50% after FDA rejects lead drug relacorilant; class action targets alleged disclosure failures with lead plaintiff deadline April 21, 2026.

Corcept Therapeutics faces securities class action over allegedly misleading statements about relacorilant's FDA approval prospects, triggering 50% stock plunge and $3.6B market cap loss.

Class actions filed against PomDoctor for stock promotion fraud and Inovio for misleading regulatory claims. Inovio stock plunged 24.45% after FDA rejection.

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.

Portnoy Law Firm sues Corcept Therapeutics over alleged misrepresentations about drug candidate relacorilant, following FDA rejection that caused stock to plummet 50%.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.